👥 Connect, learn, & collaborate with your peers! Join Dr. Smith, Dr. Gao, Alicia Morgans, MD, MPH, David Einstein, Rick Lee 이재방 & Wenxin (Vincent) Xu at the Genitourinary Cancers State of the Science Summit on July 22! Register today: hubs.li/Q03wwJx20 Mass General Cancer Center #SOSSconnects

I’m still here—because KCRS connected me to a Global community that NEVER gives up. Kidney cancer doesn’t define us. Next stop: Boston July 17th & 18th-Join Us! #KCRS2025 #AcceratingCures KidneyCAN Toni Choueiri, MD Dana-Farber Dana-Farber Lank Center for Genitourinary Oncology Michael Serzan, MD Bradley McGregor Wenxin (Vincent) Xu

Genitourinary Cancers State of the Science Summit is in Boston on July 22: Alicia Morgans, MD, MPH and Wenxin (Vincent) Xu are both presenting on new treatment approaches and strategies in genitourinary cancers. Dana-Farber Lank Center for Genitourinary Oncology

What an incredible slide from Wenxin (Vincent) Xu at #KCRS2025 depicting some of the individuals that have contributed to biomarker research in RCC 🔬. “Biomarkers are a lot of work, but they will reduce both overtreatment and undertreatment” KidneyCAN OncoAlert

Takeaways from Wenxin (Vincent) Xu 's majestic talk on biomarkers: - Several biomarkers have been studied in RCC - Current biomarkers in RCC do not correspond to patient's goals - The future is in integrative biomarkers - Let's get back to work to answer all the different questions

#KCRS25 Session 5 focused on current best practices and what's ahead in kidney cancer treatment and research. Front-Line Treatment Approaches with David McDermott Subsequent-Line Options with Robert Motzer MD Adjuvant Therapy Options with Naomi Haas Treatment of Rare Subtypes with

🚨Internal medicine applicant Marc Machaalani, MD presents the work on KIM-1 like a pro⭐️ KIM-1 is a promising biomarker as well as a great reflection of broader tumor biology #KCRS25 OncoAlert

A sharp and insightful talk at #KCRS25 about KIM-1 in JAVELIN Renal 101 by my dear colleague Marc Machaalani, MD — another key step in the evolving story of KIM-1 in RCC with more to come!! Wenxin (Vincent) Xu Toni Choueiri, MD

KIM-1 Represents a Potential Biomarker for Outcomes and Response in RCC #KCRS25 #RCC Wenxin (Vincent) Xu Dana-Farber News onclive.com/view/kim-1-rep…

And that is wrap for #KCRS2025 Hans Hammers Bryan Lewis KidneyCAN

Just 1 week away! Please join me in #PMC2025 #CloserByTheMile. Fighting cancer is more important now than ever. 100% of all donations support cancer research at Dana-Farber Cancer Institute. profile.pmc.org/WX0001

Wenxin (Vincent) Xu Thanks, Dr. Xu, for riding again this year - it means so much to patients and their families. John & I send wishes for a safe and enjoyable ride. We’ll see you soon.

Please check out our editorial just out in Nature Reviews Urology on a pragmatic approach to biomarkers for RCC! Many challenges, but with now some emerging promising biomarkers! ari hakimi Ed Reznik Robert Motzer MD Memorial Sloan Kettering Cancer Center MSK Department of Medicine nature.com/articles/s4158…

We are #CloserByTheMile. We are all Pan-Mass Challenge strong ! Here members of Dana-Farber Lank Center for Genitourinary Oncology and Team_More_Cowbell off for #PMC2025. One goal, one mission=> Cure #cancer Dana-Farber with Marc Mombourquette

Pan-Mass Challenge Dana-Farber Lank Center for Genitourinary Oncology today’s the day! One mile at a time for all who come to DFCI! Cheering on my friends riding today! Bradley McGregor Alok Tewari Wenxin (Vincent) Xu Toni Choueiri, MD

Day 1 of #PMC2025 in the books! Crossing the finish line was epic ! Together with the Pan-Mass Challenge efforts, we will cure #cancer @danafarber. A salute to @cowbellteam + Dana-Farber_GU members Michael Serzan, MD Wenxin (Vincent) Xu Bradley McGregor Marc Mombourquette Dear Dr. Researcher, PhD Alok Tewari +many more!

The biomarker KIM-1 has emerged as a potential prognostic indicator for response to therapy and could be used to inform clinical decision making for patients with #RCC. Wenxin (Vincent) Xu Dana-Farber News Read here: hubs.li/Q03BWk3B0

The biomarker KIM-1 has emerged as a potential prognostic indicator for response to therapy and could be used to inform clinical decision making for patients with #RCC.Wenxin (Vincent) Xu Dana-Farber News Read here: hubs.li/Q03BWk3B0

At #KCRS25, Wenxin (Vincent) Xu of Dana-Farber News discussed the potential for KIM-1 as a prognostic biomarker for response to therapy, which could be used to help inform clinical decision making for the treatment of patients with #RCC. Read here for more: hubs.li/Q03BWhY60

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…